Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

Lee, K H; Talpaz, M; Rothberg, J M; Murray, J L; Papadopoulos, N; Plager, C; Benjamin, R; Levitt, D; Gutterman, J

Lee, K H; Talpaz, M; Rothberg, J M; Murray, J L; Papadopoulos, N; Plager, C; Benjamin, R; Levitt, D; Gutterman, J.

Affiliation

Lee KH; Department of Clinical Immunology and Biological Therapy, University of Texas M.D. Anderson Cancer Center, Houston 77030.

J Clin Oncol ; 7(11): 1726-32, 1989 Nov.

Article in En | MEDLINE | ID: mdl-2809685

Subject(s)

Immunologic Factors/administration & dosage; Interferon Type I/administration & dosage; Interleukin-2/administration & dosage; Melanoma/therapy; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Drug Evaluation; Drug Tolerance; Fatigue/chemically induced; Fever/chemically induced; Humans; Hypotension/chemically induced; Immunologic Factors/adverse effects; Interferon Type I/adverse effects; Interleukin-2/adverse effects; Recombinant Proteins; Water-Electrolyte Balance/drug effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Interferon Type I / Interleukin-2 / Immunologic Factors / Melanoma Limits: Humans Language: En Journal: J Clin Oncol Year: 1989 Type: Article

Search on Google

XML

PubMed Links